⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
DMAC News
DiaMedica Therapeutics Inc. Common Stock
DiaMedica Therapeutics Announces 75% Enrollment Milestone in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial
businesswire.com
DMAC
DiaMedica Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
businesswire.com
DMAC
Form 8-K
sec.gov
DMAC
DiaMedica Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights
businesswire.com
DMAC
RedChip's Biotech Virtual Investor Conference Replays Now Available
accessnewswire.com
INAB
DMAC
NSRX
CLDI
RedChip's April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare Platforms
accessnewswire.com
INAB
DMAC
NSRX
CNTB
CLDI
Form 8-K
sec.gov
DMAC
DiaMedica Therapeutics Reports Full Year 2025 Financial Results and Provides Business Highlights
businesswire.com
DMAC
DiaMedica Therapeutics to Report Fourth Quarter 2025 Financial Results and Provide a Business Update March 31, 2026
businesswire.com
DMAC
DiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in Preeclampsia
businesswire.com
DMAC